CD38 and systemic lupus erythematosus: Daratumumab is a monoclonal antibody against CD38 approved for multiple myeloma, which has been successfully used in patients with refractory SLE who previously had received bortezomib (70), lending merit for targeting terminally differentiated B cells in recalcitrant forms of SLE using one or multiple agents.